GGrantIndex
← Search

HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers

$853,006ZIAFY2022TRNIH

National Center For Advancing Translational Sciences

Investigators

Linked publications, trials & patents

Abstract

Previously we designed and synthesized novel dual HDAC/PI3K inhibitors, identifying several novel molecules that inhibit both targets with single digit nanomolar potency. Selected compounds have been tested in the NCI60 cell line panel, showing anti-proliferation and cell-killing activity in several cell lines. A subset of these were examined in cell-based target engagement assays, confirming that the dual inhibitors engage both PI3K-delta and HDAC6 in cells. The lead compound (TRND00507679) induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts from AML patients. We have developed the nano-particle formulation for TRND00507679 and TRND00421925 and studied their cellular uptake and anti-proliferative activity in several human cancer cell lines. TRND00507679 encapsulated nano-particles (TRND00507679-NPs) displayed a dose-dependent inhibition of tumor growth in an in vivo breast cancer Ehrlich ascites tumor (EAT) model. Additionally, we have also compared the tumor growth inhibition caused by PI3K-delta inhibitor, Idelalisib based nano-particles (Idelalisib-NPs) with that of TRND00507679-NPs. In contrast to Idelalisib-NPs, treatment of EAT tumors in mice was associated with substantial reduction in tumor growth by TRND00507679-NPs. The described work was published in the Journal of Medicinal Chemistry. Current efforts have resulted in the publication of an international patent titled: Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer. Additionally, filing of a joint inventorship patent between Hillstream Biopharma, Inc. and NCATS for these nano-formulated PI3K-delta/HDAC6 dual inhibitors was launched by recent submission of an Employee Invention Record (EIR) titled: Polymeric nanoparticles comprising a histone deacetylase 6/phosphoinositide 3-Kinase-delta dual inhibitor and related methods.

View original record on NIH RePORTER →